Point72 Asia Singapore Pte. Ltd. Sells 40,079 Shares of Invivyd, Inc. (NASDAQ:IVVD)

Point72 Asia Singapore Pte. Ltd. decreased its holdings in shares of Invivyd, Inc. (NASDAQ:IVVD) by 53.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,022 shares of the company’s stock after selling 40,079 shares during the quarter. Point72 Asia Singapore Pte. Ltd.’s holdings in Invivyd were worth $39,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. XTX Topco Ltd grew its stake in Invivyd by 68.1% in the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock worth $42,000 after buying an additional 15,376 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Invivyd by 198.6% during the 2nd quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock worth $42,000 after acquiring an additional 25,201 shares during the last quarter. Cornercap Investment Counsel Inc. purchased a new position in Invivyd in the second quarter worth $86,000. Rhumbline Advisers increased its stake in Invivyd by 4,434.1% in the second quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock valued at $92,000 after acquiring an additional 82,164 shares during the last quarter. Finally, Tidal Investments LLC purchased a new stake in Invivyd during the first quarter valued at about $126,000. 70.36% of the stock is currently owned by institutional investors.

Invivyd Stock Performance

Shares of Invivyd stock opened at $1.02 on Tuesday. Invivyd, Inc. has a 52-week low of $0.81 and a 52-week high of $5.20. The company has a fifty day moving average of $1.05 and a 200-day moving average of $1.79. The stock has a market capitalization of $121.70 million, a price-to-earnings ratio of -0.55 and a beta of 0.61.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.03). The business had revenue of $2.26 million for the quarter, compared to analyst estimates of $4.91 million. On average, equities research analysts forecast that Invivyd, Inc. will post -0.6 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Invivyd in a research report on Tuesday, September 3rd.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.